Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported second-quarter results that beat analyst expectations and raised its full-year forecast.
The company posted adjusted earnings of $0.54 per share, easily topping the consensus estimate of $0.45. Revenue for the quarter reached $204.1 million, an 11.9% increase from the prior year that also surpassed expectations.
Following the strong performance, Repligen increased its full-year revenue guidance to around $824 million and lifted its adjusted earnings per share outlook to a range of $2.03 to $2.09, signaling confidence in its continued performance.
Is now the time to buy Repligen? Access our full analysis report here, it's free.
Repligen's shares are quite volatile and have had 17 moves greater than 5% over the last year. But moves this big are rare even for Repligen and indicate this news significantly impacted the market's perception of the business.
The previous big move we wrote about was 4 days ago when the stock dropped 3.1% on the news that concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million in the quarter. The development raises concerns for the broader hospital industry, as a higher volume of uninsured patients generally leads to more uncompensated care, potentially squeezing profit margins for other providers as well.
Repligen is down 9.3% since the beginning of the year, and at $148.99 per share, it is trading 13.5% below its 52-week high of $172.26 from January 2026. Investors who bought $1,000 worth of Repligen's shares 5 years ago would now be looking at only $633.25.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who's building AI, one company is already using it to print money. And nobody's paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won't last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.